To extend our findings, we used two additional mouse cell lines modified to harbor KRASG12C mutations, the KRAS-mutant, p53-deleted lung cancer cell line KPB6G12C (25) and the KRAS-mutant colon cancer cell line CT26G12C (19). This evidence concerns the gene KRAS and lung carcinoma.